July 2019
Volume 60, Issue 9
Free
ARVO Annual Meeting Abstract  |   July 2019
Influence of ranibizumab on radiation retinopathy after irradiation of choroidal melanoma (RadiRet) – a randomized controlled trial
Author Affiliations & Notes
  • Antonia M Joussen
    Department of Ophthalmology, Charite, University Medicine Berlin, Berlin, Germany
  • Ira Seibel
    Department of Ophthalmology, Charite, University Medicine Berlin, Berlin, Germany
  • Martin Hellmich
    Institute of Medical Statistics and Computational Biology (IMSB, University of Cologne, Cologne, Germany
  • Footnotes
    Commercial Relationships   Antonia Joussen, Novartis (F); Ira Seibel, Novartis (F); Martin Hellmich, Novartis (F)
  • Footnotes
    Support  IIT funding by Novartis Pharmaceuticals
Investigative Ophthalmology & Visual Science July 2019, Vol.60, 1325. doi:
  • Views
  • Share
  • Tools
    • Alerts
      ×
      This feature is available to authenticated users only.
      Sign In or Create an Account ×
    • Get Citation

      Antonia M Joussen, Ira Seibel, Martin Hellmich; Influence of ranibizumab on radiation retinopathy after irradiation of choroidal melanoma (RadiRet) – a randomized controlled trial. Invest. Ophthalmol. Vis. Sci. 2019;60(9):1325.

      Download citation file:


      © ARVO (1962-2015); The Authors (2016-present)

      ×
  • Supplements
Abstract

Purpose : The primary objective of the RadiRet study was to demonstrate superior efficacy of ranibizumab 0.5 mg to focal and peripheral laser treatment regarding change from baseline in best-corrected visual acuity (BCVA) over 6 months in patients with retinopathy due to radiation in uveal melanoma.

Methods : A phase II, two-arm, randomized, parallel-group clinical trial. Ranibizumab was administered as three initial monthly intravitreal injections (0.5 mg, days 0, 30, 60). Subsequent injections were given if visual acuity dropped by >5 letters or evidence of macula or optic disc edema. The comparator was laser treatment of the macula and periphery. Additional treatment at intervals of not less than 3 months. Main inclusion criteria: patients with retinopathy, due to radiation of uveal melanoma (cotton wool spots, hemorrhages, vascular ischemia), visual impairment due to focal or diffuse macular edema eligible for laser treatment.

Results : The intention-to-treat analysis included 31 patients who were randomly assigned to ranibizumab (n=15) or laser treatment (n=16). The per-protocol analysis included 19 patients (7 on ranibizumab, 12 in laser group).
Efficacy: Regarding the primary outcome measure ‘average change in BCVA from baseline over 26 weeks’ treatment with ranibizumab was superior compared to laser treatment, with a mean advantage of 0.14 logMAR, p=0.030. Subgroup analyses by dose to macula/disc and gender did not indicate any interaction with treatment. Similarly treatment with ranibizumab seemed advantageous regarding the key secondary outcome ‘average change in central foveal thickness from baseline over 26 weeks’ with a mean advantage of 51.3 µm, p=0.074. The positive effect of ranibizumab vanished following week 26, i.e. after treatment was stopped.
Safety: The safety analysis was based on all patients who were treated (n=31). 11 patients experienced at least one serious adverse event.

Conclusions : This randomized controlled trial showed a statistically significant improvement of visual acuity under treatment with ranibizumab compared to laser treatment. The gain in BCVA that was seen in week 20 and 26 disappeared at week 52 following termination of treatment, suggesting that ranibizumab injections may need to be continued over a longer period than 20 weeks.

This abstract was presented at the 2019 ARVO Annual Meeting, held in Vancouver, Canada, April 28 - May 2, 2019.

×
×

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.

×